Albagha Omar M E, Ralston Stuart H
Rheumatology Section, Molecular Medicine Centre, University of Edinburgh School of Molecular and Clinical Medicine, Western General Hospital, Edinburgh, EH4 2XU, United Kingdom.
Rheum Dis Clin North Am. 2006 Nov;32(4):659-80. doi: 10.1016/j.rdc.2006.08.001.
Over the past 10 years, many advances have been made in understanding the mechanisms by which genetic factors regulate susceptibility to osteoporosis. It has become clear from studies in man and experimental animals that different genes regulate BMD at different skeletal sites and in men and women. Linkage studies have identified several chromosomal regions that regulate BMD, but only a few causative genes have been discovered so far using this approach. In contrast, significant advances have been made in identifying the genes that cause monogenic bone diseases, and polymorphic variation is some of these genes has been found to contribute to the genetic regulation of BMD in the normal population. Other genes that have been investigated as possible candidates for susceptibility to osteoporosis because of their role in bone biology, such as vitamin D, have yielded mixed results. Many candidate gene association studies have been underpowered, and meta-analysis has been used to try to confirm or refute potential associations and gain a better estimate of their true effect size in the population. Most of the genetic variants that confer susceptibility to osteoporosis remain to be discovered. It is likely that new techniques such as whole-genome association will provide new insights into the genetic determinants of osteoporosis and will help to identify genes of modest effect size. From a clinical standpoint, genetic variants that are found to predispose to osteoporosis will advance our understanding of the pathophysiology of the disease. They could be developed as diagnostic genetic tests or form molecular targets for design of new drugs for the prevention and treatment of osteoporosis and other bone diseases.
在过去十年中,我们在理解遗传因素调节骨质疏松易感性的机制方面取得了许多进展。从对人类和实验动物的研究中可以清楚地看出,不同基因在不同骨骼部位以及男性和女性中调节骨密度。连锁研究已经确定了几个调节骨密度的染色体区域,但到目前为止,使用这种方法仅发现了少数致病基因。相比之下,在确定导致单基因骨病的基因方面取得了重大进展,并且发现这些基因中的一些多态性变异有助于正常人群中骨密度的遗传调节。由于其在骨生物学中的作用而被研究作为骨质疏松易感性可能候选基因的其他基因,如维生素D,结果不一。许多候选基因关联研究的样本量不足,因此已采用荟萃分析来试图证实或反驳潜在的关联,并更好地估计它们在人群中的真实效应大小。大多数导致骨质疏松易感性的基因变异仍有待发现。全基因组关联等新技术可能会为骨质疏松的遗传决定因素提供新的见解,并有助于识别效应大小适中的基因。从临床角度来看,发现易患骨质疏松的基因变异将增进我们对该疾病病理生理学的理解。它们可以开发成诊断性基因检测方法,或者成为设计预防和治疗骨质疏松及其他骨病新药的分子靶点。